QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
NYSE:DHR

Danaher (DHR) Stock Price, News & Analysis

$245.88
-0.76 (-0.31%)
(As of 02/8/2024 ET)
Compare
Today's Range
$244.08
▼
$246.80
50-Day Range
$217.49
▼
$248.20
52-Week Range
$182.09
▼
$249.89
Volume
1.77 million shs
Average Volume
3.11 million shs
Market Capitalization
$181.69 billion
P/E Ratio
38.48
Dividend Yield
0.39%
Price Target
$266.00
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Danaher MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
8.2% Upside
$266.00 Price Target
Short Interest
Healthy
0.89% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.34
Upright™ Environmental Score
News Sentiment
0.27mentions of Danaher in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$816,724 Sold Last Quarter
Proj. Earnings Growth
13.56%
From $7.67 to $8.71 Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.77 out of 5 stars

Multi-Sector Conglomerates Sector

3rd out of 17 stocks

Process Control Instruments Industry

3rd out of 12 stocks

See Top Rated MarketRank™ Stocks Here

DHR stock logo

About Danaher Stock (NYSE:DHR)

Danaher Corporation, founded in 1984 by brothers Stephen and Mitchell Rales, is a globally diversified conglomerate headquartered in Washington, D.C. The company has evolved into a major player across various industries, offering a wide range of products and services in the medical, industrial, and commercial sectors. Danaher's mission is to innovate and provide high-quality solutions that positively impact people's lives worldwide. Danaher's began in 1984 as a Massachusetts real estate investment trust called DMG, Inc. The company underwent several reorganizations and strategic acquisitions, culminating in its present-day structure and diverse product portfolio.

Danaher is involved in designing, manufacturing, and marketing a broad array of products and services. Its offerings span medical diagnostics equipment, life sciences and diagnostics tools, environmental solutions, water quality analysis systems, industrial automation tools, and other specialized instruments. Danaher's mission is to leverage its technological expertise and commitment to continuous improvement to develop innovative solutions that enhance human well-being and drive sustainable growth.

The company's diverse product portfolio includes cutting-edge medical diagnostic devices, scientific instruments used in research and healthcare settings, water quality monitoring systems, and automation equipment for industrial applications. Danaher caters to various markets, including healthcare, life sciences, diagnostics, environmental monitoring, and industrial automation. Its products and services find applications in research institutions, healthcare facilities, industrial manufacturers, and government organizations.

Danaher Corporation boasts a leadership team comprising highly accomplished individuals with diverse expertise, driving the company's success and strategic direction. At the helm is Steven M. Rales, the Co-Founder and Chairman, who played a pivotal role in establishing Danaher and has been instrumental in shaping its strategic vision. With his visionary approach, Rales has steered the company towards sustained growth and innovation. Rainer M. Blair holds the positions of President, Chief Executive Officer, and Director, leading Danaher's day-to-day operations and spearheading its growth strategies. Blair's dynamic leadership has been crucial in driving the company's expansion and ensuring its position as a market leader.

Danaher has displayed excellent financial performance in recent years, with consistent revenue growth and profitability. The company's financial stability and strategic acquisitions have contributed to its robust performance. Danaher's strong financials indicate its ability to generate revenue and profits, which has positively influenced investor sentiment and contributed to its favorable valuation.

Danaher's valuation metrics demonstrate positive investor sentiment and confidence in the company's future growth prospects. Its favorable price-to-earnings ratio and price-to-cash flow ratio reflect investor willingness to pay a premium for its earnings potential and cash generation capacity. Danaher's stock performance has been noteworthy, driven by its strong financials, strategic initiatives, and positive market sentiment.

Investors should closely monitor any recent news or events that may have impacted Danaher's share price, such as industry developments or major acquisitions. Danaher operates in diverse industries with various competitors. Its competitive advantages, including a broad product portfolio and emphasis on innovation, position it well within its industries.

Danaher has ample growth opportunities, including expansion into emerging markets, strategic acquisitions, and research and development investments. The company's strong focus on continuous improvement and customer-centric solutions will drive its pursuit of growth opportunities.

Danaher faces potential risks and challenges, including market fluctuations, regulatory changes, and economic uncertainties. However, its proactive risk management strategies mitigate potential impacts on the company's financial performance.

DHR Stock Price History

DHR Stock News Headlines

January 10, 2024 | marketbeat.com
Will Danaher stock hit new highs in 2024?
Danaher raises guidance, sending shares higher, but the move may not last. Resistance is just above current levels and may cap gains until later in the year.
February 7, 2024 | finance.yahoo.com
Carlisle (CSL) Q4 Earnings Beat Estimates, Revenues Decline Y/Y
February 8, 2024 | Stansberry Research (Ad)
HUGE BUY ALERT: Move Fast, Musk…
Since 2018, Eric Wade's investment recommendations have averaged 115%. But one investment he just discovered in Phoenix could blow them all away. It involves Elon Musk, Bill Gates, 32 government mandates, and an AI breakthrough... Not to mention a technology that could help you earn $30,000 a year outside the stock market. 
February 5, 2024 | markets.businessinsider.com
Danaher, Cincinnati Children's Hospital Partner To Improve Patient Safety In Early Clinical Trials
February 4, 2024 | americanbankingnews.com
Analysts Offer Predictions for Danaher Co.'s Q2 2025 Earnings (NYSE:DHR)
February 4, 2024 | americanbankingnews.com
Danaher Co. Forecasted to Earn Q2 2024 Earnings of $1.61 Per Share (NYSE:DHR)
February 3, 2024 | americanbankingnews.com
Danaher (NYSE:DHR) Price Target Increased to $290.00 by Analysts at KeyCorp
February 2, 2024 | americanbankingnews.com
Royal Bank of Canada Increases Danaher (NYSE:DHR) Price Target to $282.00
February 8, 2024 | The Oxford Club (Ad)
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
February 2, 2024 | americanbankingnews.com
Citigroup Increases Danaher (NYSE:DHR) Price Target to $280.00
February 2, 2024 | americanbankingnews.com
William Blair Analysts Decrease Earnings Estimates for Danaher Co. (NYSE:DHR)
February 1, 2024 | finance.yahoo.com
Danaher Corporation (NYSE:DHR) Q4 2023 Earnings Call Transcript
February 1, 2024 | americanbankingnews.com
Danaher (NYSE:DHR) Given New $270.00 Price Target at Raymond James
February 1, 2024 | americanbankingnews.com
Brokers Offer Predictions for Danaher Co.'s Q1 2024 Earnings (NYSE:DHR)
February 1, 2024 | americanbankingnews.com
Danaher (NYSE:DHR) Stock Rating Lowered by StockNews.com
February 1, 2024 | americanbankingnews.com
Danaher (NYSE:DHR) Hits New 12-Month High on Strong Earnings
January 31, 2024 | realmoney.thestreet.com
Danaher price target raised by $25 at Citi, here's why
January 31, 2024 | markets.businessinsider.com
Optimistic Outlook for Danaher: Buy Rating Affirmed Amid Recovery and Improved Target Price
January 31, 2024 | markets.businessinsider.com
Danaher Analysts Increase Their Forecasts After Upbeat Earnings
January 31, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Danaher with Increased Price Target Amid Strong Growth and Conservative Guidance
January 31, 2024 | finance.yahoo.com
Q4 2023 Danaher Corp Earnings Call
January 30, 2024 | msn.com
Danaher (DHR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
January 30, 2024 | realmoney.thestreet.com
How Does Danaher Stock Look After Earnings?
January 30, 2024 | msn.com
Danaher (NYSE:DHR) Drops on Dismal Q4 Numbers
January 30, 2024 | finance.yahoo.com
Life Science Giant Danaher Warns Of Sales Decline In 2024; Says 'Pandemic Has Transitioned To An Endemic State'
January 30, 2024 | seekingalpha.com
Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term
January 30, 2024 | investing.com
Danaher shares fall as Q4 FCF comes in sharply below consensus
See More Headlines
Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/26 Dividend
12/28/2023
Dividend Payable
1/26/2024
Last Earnings
1/30/2024
Today
2/08/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Multi-Sector Conglomerates
Industry
Process control instruments
Sub-Industry
Industrial Conglomerates
Current Symbol
NYSE:DHR
CUSIP
23585110
CIK
313616
Web
www.danaher.com
Phone
(202) 828-0850
Fax
202-828-0860
Employees
81,000
Year Founded
1984

Price Target and Rating

Average Stock Price Target
$266.00
High Stock Price Target
$300.00
Low Stock Price Target
$205.00
Potential Upside/Downside
+8.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
15 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$6.39
Trailing P/E Ratio
38.48
Forward P/E Ratio
32.06
P/E Growth
3.75
Net Income
$4.76 billion
Net Margins
17.26%
Pretax Margin
21.11%
Return on Equity
12.25%
Return on Assets
7.43%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
1.68
Quick Ratio
1.37

Sales & Book Value

Annual Sales
$23.89 billion
Price / Sales
7.61
Cash Flow
$10.50 per share
Price / Cash Flow
23.42
Book Value
$72.39 per share
Price / Book
3.40

Miscellaneous

Outstanding Shares
738,930,000
Free Float
656,906,000
Market Cap
$181.69 billion
Optionable
Optionable
Beta
0.85

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report














DHR Stock Analysis - Frequently Asked Questions

Should I buy or sell Danaher stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DHR shares.
View DHR analyst ratings or view top-rated stocks.

What is Danaher's stock price target for 2024?

15 equities research analysts have issued 1 year price targets for Danaher's stock. Their DHR share price targets range from $205.00 to $300.00. On average, they expect the company's stock price to reach $266.00 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price.
View analysts price targets for DHR or view top-rated stocks among Wall Street analysts.

How have DHR shares performed in 2024?

Danaher's stock was trading at $231.34 at the beginning of 2024. Since then, DHR shares have increased by 6.3% and is now trading at $245.88.
View the best growth stocks for 2024 here.

Are investors shorting Danaher?

Danaher saw a decrease in short interest in January. As of January 15th, there was short interest totaling 6,010,000 shares, a decrease of 8.9% from the December 31st total of 6,600,000 shares. Based on an average trading volume of 3,010,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 0.9% of the company's stock are short sold.
View Danaher's Short Interest.

When is Danaher's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our DHR earnings forecast.

How were Danaher's earnings last quarter?

Danaher Co. (NYSE:DHR) posted its quarterly earnings results on Tuesday, January, 30th. The conglomerate reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.18. The conglomerate earned $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a trailing twelve-month return on equity of 12.25% and a net margin of 17.26%. The firm's quarterly revenue was down 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.87 EPS.
Read the conference call transcript.

How often does Danaher pay dividends? What is the dividend yield for Danaher?

Danaher announced a quarterly dividend on Tuesday, December 5th. Investors of record on Friday, December 29th will be given a dividend of $0.24 per share on Friday, January 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Thursday, December 28th.
Read our dividend analysis for DHR.

Is Danaher a good dividend stock?

Danaher (NYSE:DHR) pays an annual dividend of $0.96 per share and currently has a dividend yield of 0.39%. The dividend payout ratio is 15.02%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DHR will have a dividend payout ratio of 11.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DHR.

What ETFs hold Danaher's stock?

ETFs with the largest weight of Danaher (NYSE:DHR) stock in their portfolio include Invesco Global Water ETF (PIO), Invesco Water Resources ETF (PHO), Alpha Intelligent - Large Cap Growth ETF (AILG), Franklin Genomic Advancements ETF (HELX), Pacer BioThreat Strategy ETF (VIRS), God Bless America ETF (YALL), Putnam BioRevolution ETF (SYNB) and First Trust Water ETF (FIW).

What is Rainer M. Blair's approval rating as Danaher's CEO?

27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Glassdoor.com. Rainer M. Blair has an approval rating of 98% among the company's employees. This puts Rainer M. Blair in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Danaher own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Danaher investors own include NVIDIA (NVDA), Home Depot (HD), Walt Disney (DIS), Johnson & Johnson (JNJ), Adobe (ADBE), Intel (INTC), Alibaba Group (BABA), Mastercard (MA), PayPal (PYPL) and AbbVie (ABBV).

Who are Danaher's major shareholders?

Danaher's stock is owned by many different retail and institutional investors. Top institutional shareholders include Flossbach Von Storch AG (0.62%), Fisher Asset Management LLC (0.57%), Charles Schwab Investment Management Inc. (0.50%), Dimensional Fund Advisors LP (0.45%), Principal Financial Group Inc. (0.42%) and Mitsubishi UFJ Asset Management Co. Ltd. (0.39%). Insiders that own company stock include Alan G Spoon, Angela S Lalor, Angela S Lalor, Brian W Ellis, Daniel Raskas, Elias A Zerhouni, Georgeann Couchara, Jennifer Honeycutt, Joakim Weidemanis, Jose-Carlos Gutierrez-Ramos, Linda Filler, Linda P Hefner, Matthew Mcgrew, Mitchell P Rales, Rainer Blair, Raymond C Stevens, Robert S Lutz, Teri List and Walter G Lohr.
View institutional ownership trends.

How do I buy shares of Danaher?

Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Danaher have any subsidiaries?
The following companies are subsidiares of Danaher: AB SCIEX, AB Sciex LLC, AB Sciex LP, AB Sciex Pte Ltd., Accu-Sort Systems, Acme Cleveland Corporation, Advanced Vision Technology, Aldevron, Aldevron L.L.C., American Precision Industries, Applied Biosystems, Applitek NV, Aquatic Infomatics ULC, Aquatic Informatics, Armstrong Tools, BC Distribution BV, Beckman Coulter, Beckman Coulter Australia Pty Ltd, Beckman Coulter Biotechnology Suzhou Co. Ltd., Beckman Coulter Canada LP, Beckman Coulter Commercial Enterprise China Co. Ltd., Beckman Coulter France S.A.S., Beckman Coulter G.m.b.H., Beckman Coulter Genomics Inc., Beckman Coulter Hong Kong Limited, Beckman Coulter Inc., Beckman Coulter India Private Limited, Beckman Coulter International SA, Beckman Coulter International Shanghai Trading Co., Beckman Coulter Ireland Inc., Beckman Coulter K.K., Beckman Coulter Korea Ltd, Beckman Coulter Laboratory Systems Suzhou Co. Ltd., Beckman Coulter Limited Liability Company, Beckman Coulter Nederland B.V., Beckman Coulter Nippon GK, Beckman Coulter S.L.U., Beckman Coulter Saudi Arabia Co.Ltd., Beckman Coulter Srl, Beckman Coulter Taiwan Inc., Beckman Coulter United Kingdom Limited, Beckman Coulter de Mexico S.A. de C.V., Beckman Finance ApS, Biacore International AB, Biosafe S.A., Blue Software LLC, Cepheid, Cepheid AB, Cepheid Canada ULC, Cepheid Europe SAS, Cepheid GmbH, Cepheid HBDC SAS, Cepheid India Private Limited, Cepheid UK Ltd., ChemTreat, ChemTreat Inc., Cispus Hong Kong Holding Limited, Cytiva, Cytiva BioProcess R&D AB, Cytiva Biotechnology Guangzhou Co. Ltd., Cytiva Biotechnology Hang Zhou Co. Ltd., Cytiva Europe GmbH, Cytiva Sweden AB, DCHL Holding BV, DH Denmark Holding ApS, DH Europe Finance II Sarl, DH Europe Finance Sarl, DH Holding Italia SRL, DH Holdings Germany LLC, DH II Luxembourg Sarl, DH Japan Finance Sarl, DH Switzerland Finance Sarl, DH Technologies Development Pte Ltd., DHCY Limited, DHKAB Company AB, DTIL Ireland Holdings Ltd., Danaher China Holdings Ltd., Danaher Finance Company AB, Danaher HK Holdings Ltd., Danaher Medical ApS, Danaher Shanghai Management Co. Ltd., Delta Consolidated Industries, Devicore Medical Products Inc., Easco Hand Tools, Esko, Esko BV, Esko Graphics BV, Esko Graphics Inc., Esko Software BV, Fluke, GE Biopharma, Gelman Sciences Inc., Gendex, Genetix Group, Gilbarco Veeder Root, Gilzoni Ltd., Global Life Sciences Solutions Austria GmbH & Co. KG, Global Life Sciences Solutions Germany GmbH, Global Life Sciences Solutions Korea Ltd., Global Life Sciences Solutions Manufacturing UK Ltd, Global Life Sciences Solutions Operations UK Ltd, Global Life Sciences Solutions Singapore Pte Ltd, Global Life Sciences Solutions USA LLC, Global Life Sciences Technologies Japan KK, Global Life Sciences Technologies Shanghai Co Ltd., Hach Company, Hach Lange GmbH, Hach Lange Sàrl, Hach Water Quality Analytical Instru. Shanghai Co. Ltd., HemoCue AB, HyClone Laboratories LLC, Hybritech Incorporated, Hyclone Life Sciences Solutions India Private Limited, ID Business Solutions Limited, IDBS Group, IRIS International, Imaging Sciences International, Immunotech Sro, Intabio LLC, Integrated DNA Technologies, Integrated DNA Technologies BVBA, Integrated DNA Technologies Inc., Integrated DNA Technologies Pte. Ltd., Intermountain Life Sciences LLC, Iris International Inc., KaVo, KaVo Kerr, Kaltenbach & Voigt, Keithley Instruments, Kipp & Zonen BV, Kollmorgen, Labcyte Inc., Laetus, Launchchange Holding Company, Leica Biosystems Imaging Inc., Leica Biosystems Melbourne Pty Ltd, Leica Biosystems Newcastle Limited, Leica Biosystems Nussloch GmbH, Leica Biosystems Richmond Inc., Leica Instruments Singapore Pte Limited, Leica Microsystems, Leica Microsystems CMS GmbH, Leica Microsystems Cambridge Limited, Leica Microsystems IR GmbH, Leica Microsystems Inc., Leica Microsystems Limited, Leica Microsystems UK Limited, Leica Mikrosysteme GmbH, Leica Mikrosysteme Vertrieb GmbH, Life Sciences Holdings France SAS, Life Sciences IP Holdings Corporation, Lifschultz Industries, Linx Printing Technologies, Linx Printing Technologies Limited, MDS Analytical Technologies, Marconi Data Systems, Microtest, Molecular Devices, Molecular Devices LLC, Navman Wireless, Navman Wireless OEM Solutions, Nihon Pall Ltd., Nobel Biocare, OTT Hydromet Corp, Pall Aeropower Corporation, Pall Artelis BVBA, Pall Asia Holdings Inc., Pall Austar Lifesciences Limited, Pall Australia Pty. Ltd., Pall Austria Filter Ges.m.b.h, Pall Canada ULC, Pall China Co. Ltd., Pall Corporation, Pall Europe Limited, Pall Filtersystems GmbH, Pall Filtration Pte. Ltd., Pall Filtration and Separations Group Inc., Pall France SAS, Pall GmbH, Pall India Pvt. Ltd., Pall International Sarl, Pall Italia Srl, Pall Korea Ltd., Pall Life Sciences Belgium BV, Pall Life Sciences Puerto Rico LLC, Pall Manufacturing UK Limited, Pall Medistad BV, Pall Netherlands BV Irish Branch, Pall Schweiz GmbH, Pall Technology UK Limited, PaloDEX, Pantone LLC, Pelton & Crane, Phenomenex, Phenomenex Inc., Precision NanoSystems, Precision Nanosystems ULC, Radiometer, Radiometer Medical ApS, Radiometer Turku Oy, Raytek, Reytek Corporation, Sea-Bird Electronics Inc., Sedaru Inc., Shanghai AB Sciex Analytical Instrument Trading Co. Ltd., Skyland Analytics Inc., Sutron, Swift Biosciences Inc., Sybron Dental Specialties, Tektronix, Thomson Industries, Trojan Technologies, Trojan Technologies Group ULC, VSS Monitoring, Vanrx Pharmasystems Inc., Videojet Do Brasil Comércio de Equipamentos Para Codificação Industrial Ltda., Videojet Technologies Europe B.V., Videojet Technologies GmbH, Videojet Technologies Inc., Videojet Technologies S Pte.Ltd., Viridor Waste Management Limited, Vision Systems Limited, Willett International, X-Ray Optical Systems Inc., X-Rite, X-Rite Europe GmbH, X-Rite Incorporated, XOS, Yukon Hong Kong Holding Limited, and Zhuhai S.E.Z. Videojet Electronics Ltd..
Read More
This page (NYSE:DHR) was last updated on 2/8/2024 by MarketBeat.com Staff

My Account -